Results Provide Encouraging Outlook for Extended Treatment of Glaucoma Patients

RESEARCH TRIANGLE PARK, NC – FEBRUARY 3, 2017 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today released an interim analysis of the second cohort of its ENV515 (travoprost XR) phase 2 trial in patients with glaucoma showing a clinically meaningful reduction in intraocular pressure (IOP) for the entire 11-month evaluation period following a single administration. ENV515 also demonstrated an IOP lowering effect comparable to prestudy topical prostaglandin analogs (XALATAN® and LUMIGAN®) and in-study topical timolol maleate 0.5% ophthalmic solution (daily eye drops). Glaucoma is the leading cause of preventable vision loss and blindness due largely in part to poor patient compliance with once-daily eye drops. Read more here.

Results Provide Encouraging Outlook for Extended Treatment of Glaucoma Patients

 RESEARCH TRIANGLE PARK, NC – OCTOBER 17, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today released an interim analysis of its ENV515 (travoprost XR) phase 2 trial in glaucoma patients showing clinically meaningful reduction in intraocular pressure (IOP) for the entire nine-month evaluation period following a single administration. ENV515 also demonstrated an IOP lowering effect comparable to prestudy topical prostaglandin analogs (XALATAN® and LUMIGAN®) and in-study topical timolol maleate 0.5% ophthalmic solution (daily eye drops). Glaucoma is the leading cause of preventable vision loss and blindness due largely in part to poor patient compliance with once-daily eye drops. Read more here.

Company to Highlight Novel Approach to Developing Extended-­‐Release Ocular Therapies

 RESEARCH TRIANGLE PARK, NC October 10, 2016 – Envisia Therapeutics today announced that it has been selected to present during the Anterior Segment Company Showcase at the 2016 Ophthalmology Innovation Summit (OIS) being held at 8:30am CDT on October 13, 2016 at the Planet Hollywood Hotel in Chicago, Illinois. Commonly referred to as OIS@AAO, the summit is held each year in conjunction with the American Academy of Ophthalmology (AAO) Annual Meeting to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. Read more here.

RESEARCH TRIANGLE PARK, NCSeptember 1, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, announced today that Dr. Benjamin Yerxa will participate in a panel titled “Emerging Innovators – An Introduction to Private Biotech Companies” at Citi’s 11th Annual Biotech Conference in Boston, MA on Thursday, September 8, 2016.  Read more here.

RESEARCH TRIANGLE PARK, NCAugust 10, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, announced today that Dr. Benjamin Yerxa will present at the Wedbush PacGrow Healthcare Conference in New York, NY on Wednesday, August 17, 2016.  Read more…

RESEARCH TRIANGLE PARK, NC – July 27, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, announced today that it will present at the Ophthalmic Drug Development Summit taking place July 26 – 28, 2016 in Washington, DC. Read More

RESEARCH TRIANGLE PARK, NC – May 3, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported positive results from an interim three-month analysis of an ongoing 12-month safety and efficacy evaluation of the low dosage form of ENV515 XR (travoprost). Read More…

RESEARCH TRIANGLE PARK, NC – May 1, 2016 – Company to Deliver Eight Data Presentations at World’s Largest Ophthalmology Gathering. Envisia Therapeutics today announced that eight posters have been selected for presentation at the Association for Research in Vision and Ophthalmology’s (ARVO) Annual Meeting being held May 1 – 5, 2016 in Seattle, WA. Read More…

RESEARCH TRIANGLE PARK, NC – March 23, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today announced a $16.5 million investment from existing investors to support the accelerated development of the Company’s pipeline of innovative extended-release ocular therapies for the three leading causes of preventable vision loss and blindness. Read More…

RESEARCH TRIANGLE PARK, NC – January 12, 2016 – Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today announced it has dosed its first patient in the second cohort of the phase 2 clinical program evaluating the Company’s  lead  product  candidate,  ENV515. ENV515 is an extended-release formulation of travoprost that could offer sustained reduction in intraocular pressure (IOP) for more than six months after a single dose. Read More…


1 2 3
Copyright 2013 Envisia Therapeutics